Source: Health Products Regulatory Authority (IE) Revision Year: 2023 Publisher: Aspen Pharma Trading Limited, 3016 Lake Drive, Citywest Business Campus, Dublin 24, Ireland
Ultiva 1 mg Powder for Concentrate for Solution for Infusion.
| Pharmaceutical Form |
|---|
|
Powder for concentrate for solution for infusion. A white to off-white, lyophilised powder. |
1 vial contains 1 mg remifentanil (as remifentanil hydrochloride).
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Remifentanil |
Remifentanil is a selective mu-opioid agonist with a rapid onset and very short duration of action. The mu-opioid activity, of remifentanil, is antagonised by narcotic antagonists, such as naloxone. |
| List of Excipients |
|---|
|
Glycine |
Ultiva injection for intravenous use is available as a glass vial with rubber stopper and aluminium overseal:
1 mg Remifentanil lyophilised powder in 3 ml vials in cartons of 5.
Not all pack sizes may be marketed.
Aspen Pharma Trading Limited, 3016 Lake Drive, Citywest Business Campus, Dublin 24, Ireland
PA1691/032/001
Date of first authorisation: 27 May 1999
Date of last renewal: 27 May 2009
| Drug | Countries | |
|---|---|---|
| ULTIVA | Austria, Brazil, Cyprus, Ecuador, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
